These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 25952367)

  • 1. Cognitive and affective benefits of combination therapy with galantamine plus cognitive rehabilitation for Alzheimer's disease.
    Tokuchi R; Hishikawa N; Matsuzono K; Takao Y; Wakutani Y; Sato K; Kono S; Ohta Y; Deguchi K; Yamashita T; Abe K
    Geriatr Gerontol Int; 2016 Apr; 16(4):440-5. PubMed ID: 25952367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer's disease with cerebrovascular disease.
    Small G; Erkinjuntti T; Kurz A; Lilienfeld S
    CNS Drugs; 2003; 17(12):905-14. PubMed ID: 12962529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns of decline and evidence of subgroups in patients with Alzheimer's disease taking galantamine for up to 48 months.
    Rockwood K; Dai D; Mitnitski A
    Int J Geriatr Psychiatry; 2008 Feb; 23(2):207-14. PubMed ID: 17621382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A naturalistic study of galantamine for Alzheimer's disease.
    Brodaty H; Woodward M; Boundy K; Barnes N; Allen G;
    CNS Drugs; 2006; 20(11):935-43. PubMed ID: 17044730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial.
    Raskind MA; Peskind ER; Truyen L; Kershaw P; Damaraju CV
    Arch Neurol; 2004 Feb; 61(2):252-6. PubMed ID: 14967774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong.
    Chu LW; Yik PY; Mok W; Chung CP
    Int J Clin Pract; 2007 Mar; 61(3):403-10. PubMed ID: 17313606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial.
    Erkinjuntti T; Kurz A; Gauthier S; Bullock R; Lilienfeld S; Damaraju CV
    Lancet; 2002 Apr; 359(9314):1283-90. PubMed ID: 11965273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cognitive rehabilitation combined with drug treatment in Alzheimer's disease patients: a pilot study.
    Bottino CM; Carvalho IA; Alvarez AM; Avila R; Zukauskas PR; Bustamante SE; Andrade FC; Hototian SR; Saffi F; Câmargo CH
    Clin Rehabil; 2005 Dec; 19(8):861-9. PubMed ID: 16323385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carotid intima-media thickness as a predictor of response to cholinesterase inhibitors in Alzheimer's disease: an open-label trial.
    Modrego PJ; Rios C; Pérez Trullen JM; García-Gómara MJ; Errea JM
    CNS Drugs; 2009; 23(3):253-60. PubMed ID: 19320533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective study on the benefits of combined Memantine and cholinEsterase inhibitor treatMent in AGEd Patients affected with Alzheimer's Disease: the MEMAGE study.
    Gareri P; Putignano D; Castagna A; Cotroneo AM; De Palo G; Fabbo A; Forgione L; Giacummo A; Lacava R; Marino S; Simone M; Zurlo A; Putignano S
    J Alzheimers Dis; 2014; 41(2):633-40. PubMed ID: 24643135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease.
    Brodaty H; Corey-Bloom J; Potocnik FC; Truyen L; Gold M; Damaraju CR
    Dement Geriatr Cogn Disord; 2005; 20(2-3):120-32. PubMed ID: 15990426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effects of galantamine on cognitive function in Alzheimer's disease: a large-scale international retrospective study.
    Kavanagh S; Van Baelen B; Schäuble B
    J Alzheimers Dis; 2011; 27(3):521-30. PubMed ID: 21891871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson's disease (an open controlled trial).
    Litvinenko IV; Odinak MM; Mogil'naya VI; Emelin AY
    Neurosci Behav Physiol; 2008 Nov; 38(9):937-45. PubMed ID: 18975103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term safety and cognitive effects of galantamine in the treatment of probable vascular dementia or Alzheimer's disease with cerebrovascular disease.
    Kurz AF; Erkinjuntti T; Small GW; Lilienfeld S; Damaraju CR
    Eur J Neurol; 2003 Nov; 10(6):633-40. PubMed ID: 14641507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer's disease: a 12-month, randomized, open-label trial.
    Cumbo E; Ligori LD
    J Alzheimers Dis; 2014; 39(3):477-85. PubMed ID: 24164733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risperidone, olanzapine and quetiapine in the treatment of behavioral and psychological symptoms in patients with Alzheimer's disease: preliminary findings from a naturalistic, retrospective study.
    Rocca P; Marino F; Montemagni C; Perrone D; Bogetto F
    Psychiatry Clin Neurosci; 2007 Dec; 61(6):622-9. PubMed ID: 18081622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic patterns associated with the clinical response to galantamine therapy: a fludeoxyglucose f 18 positron emission tomographic study.
    Mega MS; Dinov ID; Porter V; Chow G; Reback E; Davoodi P; O'Connor SM; Carter MF; Amezcua H; Cummings JL
    Arch Neurol; 2005 May; 62(5):721-8. PubMed ID: 15883258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Galantamine for the treatment of BPSD in Thai patients with possible Alzheimer's disease with or without cerebrovascular disease.
    Tangwongchai S; Thavichachart N; Senanarong V; Poungvarin N; Phanthumchinda K; Praditsuwan R; Nidhinandana S; Chankrachang S
    Am J Alzheimers Dis Other Demen; 2008 Dec-2009 Jan; 23(6):593-601. PubMed ID: 18845693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the efficacy of a cognitive rehabilitation treatment on a group of Alzheimer's patients with moderate cognitive impairment: a pilot study.
    Salotti P; De Sanctis B; Clementi A; Fernandez Ferreira M; De Silvestris T
    Aging Clin Exp Res; 2013 Aug; 25(4):403-9. PubMed ID: 23760946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of intensive cognitive rehabilitation and donepezil therapy in Alzheimer's disease (AD).
    Giordano M; Dominguez LJ; Vitrano T; Curatolo M; Ferlisi A; Di Prima A; Belvedere M; Barbagallo M
    Arch Gerontol Geriatr; 2010; 51(3):245-9. PubMed ID: 19969381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.